AU2000279614A1 - Remedies for endothelin-induced diseases - Google Patents

Remedies for endothelin-induced diseases

Info

Publication number
AU2000279614A1
AU2000279614A1 AU2000279614A AU7961400A AU2000279614A1 AU 2000279614 A1 AU2000279614 A1 AU 2000279614A1 AU 2000279614 A AU2000279614 A AU 2000279614A AU 7961400 A AU7961400 A AU 7961400A AU 2000279614 A1 AU2000279614 A1 AU 2000279614A1
Authority
AU
Australia
Prior art keywords
endothelin
remedies
induced diseases
diseases
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2000279614A
Inventor
Akira Fujimori
Hironori Harada
Akiko Koakutsu
Mikiko Mori
Masanao Sanagi
Nobuyuki Yamamoto
Hironori Yuyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of AU2000279614A1 publication Critical patent/AU2000279614A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
AU2000279614A 2000-02-16 2000-10-27 Remedies for endothelin-induced diseases Abandoned AU2000279614A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000037314 2000-02-16
JP2000037313 2000-02-16
JP2000-37314 2000-02-16
JP2000-37313 2000-02-16
PCT/JP2000/007573 WO2001060370A1 (en) 2000-02-16 2000-10-27 Remedies for endothelin-induced diseases

Publications (1)

Publication Number Publication Date
AU2000279614A1 true AU2000279614A1 (en) 2001-08-27

Family

ID=26585418

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2000279614A Abandoned AU2000279614A1 (en) 2000-02-16 2000-10-27 Remedies for endothelin-induced diseases

Country Status (15)

Country Link
US (1) US6774131B1 (en)
EP (1) EP1256344B1 (en)
JP (2) JP3832229B2 (en)
KR (1) KR20020075797A (en)
CN (1) CN1434715A (en)
AR (1) AR031679A1 (en)
AT (1) ATE348617T1 (en)
AU (1) AU2000279614A1 (en)
BR (1) BR0017120A (en)
CA (1) CA2395711A1 (en)
DE (1) DE60032517T2 (en)
ES (1) ES2277856T3 (en)
HU (1) HUP0204139A3 (en)
RU (1) RU2002124599A (en)
WO (1) WO2001060370A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
CA2677640A1 (en) * 2007-02-09 2008-08-14 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
CN101809024A (en) * 2007-07-16 2010-08-18 铂雅制药公司 The oral preparations of pyrrole platinum
WO2009099649A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
WO2009141167A1 (en) * 2008-05-23 2009-11-26 Synthon B.V. Bosentan salts
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
EP3553186B1 (en) 2012-10-12 2021-11-17 Inbiomotion, S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0000474A3 (en) 1995-12-20 2001-06-28 Astellas Pharma Inc Chuo Ku Arylethenesulfonamide derivatives and drug composition containing the same
US6030975A (en) * 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain

Also Published As

Publication number Publication date
AR031679A1 (en) 2003-10-01
EP1256344B1 (en) 2006-12-20
EP1256344A4 (en) 2004-12-29
CA2395711A1 (en) 2002-07-18
HUP0204139A2 (en) 2003-05-28
RU2002124599A (en) 2004-03-10
HUP0204139A3 (en) 2003-07-28
JP3832229B2 (en) 2006-10-11
DE60032517T2 (en) 2007-10-04
EP1256344A1 (en) 2002-11-13
ES2277856T3 (en) 2007-08-01
BR0017120A (en) 2003-01-14
WO2001060370A1 (en) 2001-08-23
DE60032517D1 (en) 2007-02-01
ATE348617T1 (en) 2007-01-15
US6774131B1 (en) 2004-08-10
KR20020075797A (en) 2002-10-05
CN1434715A (en) 2003-08-06
JP2006176542A (en) 2006-07-06
JP2001302514A (en) 2001-10-31

Similar Documents

Publication Publication Date Title
AU2001246876A1 (en) Remedies
AU2001246877A1 (en) Remedies
HUP0200994A3 (en) Remedies for immunological diseases
AU2001244188A1 (en) Medicaments against viral diseases
AU2001286221A1 (en) Remedies for ischemic diseases
AU2001269529A1 (en) Medicine comprising dicyanopyridine derivative
AU2002222118A1 (en) Pharmaceutical compositions for inhalation
AU2001252599A1 (en) Remedies for cancer
AU2000279614A1 (en) Remedies for endothelin-induced diseases
AU2002214324A1 (en) Medicinal compositions
AU2001277711A1 (en) Remedies for cisplatin-tolerant cancer
AU2001290239A1 (en) Medicinal composition
AU2001256201A1 (en) Device for administering implants
AU2002315848A1 (en) Remedies for eosinophilic diseases
AU2001241162A1 (en) Remedies for allergic diseases
AU2002215114A1 (en) Pharmaceutical compositions for inhalation
IL159478A0 (en) Remedies for eosinophilic diseases
AU2001236006A1 (en) Preventives/remedies for kidney diseases
AU2001285667A1 (en) Sanitary cigarette case
AU2001292301A1 (en) Novel drugs for liver diseases
AU2001291691A1 (en) Drugs for incontinence
AU2001271026A1 (en) Remedies for bone diseases
AU2001228863A1 (en) Remedies for ophthalmic diseases
AU2001287884A1 (en) Halogen compounds for use in medicine
AU2001282541A1 (en) Medicinal compositions